- Global Pharma News & Resources
28-Sep-2021 - 29-Sep-2021

5th Pharma Pricing, Reimbursement & Market Access 2021 (Virtual Conference)

5th Pharma Pricing, Reimbursement & Market Access 2021

“Critical guide for successfully identifying your pricing, reimbursement and market access strategies”

28th - 29th September 2021, Virtual Conference (Time Zone - EST)

This conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. It will be studied with the help of case studies and industry experiences. Following a raft of health policy reforms impacting pharmaceutical pricing in almost every major country in the EU.


Email - or TEL: +44-20 3509 3779

Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.

EARLY BIRD PRICE (Valid Till 30th August 2021 - Not Valid for UK based attendees):

1 Delegate @ £399

3 Delegates @ £999

EARLY BIRD PRICE (Valid Till 30th August 2021 – For UK based attendees):

1 Delegate @ £399+VAT

3 Delegates @ £999+VAT

STANDARD PRICE (Valid From 31st August 2021 - Not Valid for UK based attendees)

1 Delegate @ £599

3 Delegates @ £1299

STANDARD PRICE (Valid From 31st August 2021 - For UK based attendees)

1 Delegate @ £599+VAT

3 Delegates @ £1299+VAT

Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to  


  • BOXIONG TANG, Executive Director, Health Economics and Outcomes Research (HEOR), BeiGene
  • MARTIN ROST, Senior Director, Market Access (Global), Pfizer
  • JOLIE APICELLA, Assistant, U.S. Attorney’s Office, EDNY
  • YONGHUA JING , Senior Director, Health Economics and Outcomes Research, Abbvie
  • SHANTHY KRISHNARAJAH, Executive Director, Vifor Pharma
  • GARY ELLEXSON, VP Corporate Accounts, Supernus Pharmaceuticals
  • HEZEKIAH BLAKE, Director - Portfolio Planning and Market Insights, Ionis Pharmaceuticals
  • RICHARD LINER , Senior Assistant General Counsel, Bayer
  • ANGELINA IRIZARI-POLICARPIO, HEOR & Real World Evidence Leader of the U. S. Field Communications Team, Eisai
  • GREG APOSTOL, Vice President & Head of Market Access, Alkermes
  • SAMUEL MURPHY , CEO, Salubris Biotherapeutics
  • LAURENE REDDING, Head, Value, Access & Policy, BeiGene
  • MARTIJN NEGEN, VP Commercial Strategy, AM Pharma
  • TIM HERMES, VP Market Access, Trade & Patient Services, Aurinia Pharmaceuticals
  • ERIN MISTRY, SVP, Head of Payer Strategy, Gov’t Affairs & Trade, Cormedix
  • ALEXANDER NATZ, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
  • MALLORY O’CONNOR, Executive Director, Public Policy, Mallinckrodt Pharmaceuticals
  • MICHAEL THOMPSON , President & CEO, National Alliance of Healthcare Purchaser Coalitions
  • ROBERT POPOVIAN , Chief Science Policy Officer, Global Healthy Living Foundation & Senior Health Policy Fellow, Progressive Policy Institute
  • JOHN LINNELL, State Captain, COPD Foundation
  • REED STEPHENS, Partner, Winston & Strawn


  • Formulating your best market access strategy during the pandemic
  • US policy challenges for market access: Stepping ahead, especially during this Covid19
  • How to capture and quantify patient value?
  • Unrivalled opportunity to expose and address the market access challenges facing the industry
  • The role of Real World Evidence (RWE) in Oncology
  • Current & future - Challenges & opportunities in pharma pricing, reimbursement & market access
  • Improving patient and market access through the development of targeted value propositions, comprehensive contract assessment
  • Measurement strategies through to in-depth knowledge regarding payer formulary coverage trends
  • How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?
  • Understanding - payers’ perspective
  • Advocating and collaborating with payers for value in a new era
  • Creating a robust patient services and reimbursement support program for biosimilar products
  • Prioritising Patients! - Adding value through an innovative patient-centered approach
  • Understand how price affects market access and learn on how to set prices for optimal access and returns.
  • New drugs are failing to gain reimbursement from payers/HTAs at an alarming rate, despite being approved by regulators
  • Evidence Generation - The strategic rigor and creativity applied to evidence generation
  • Impact of social media and digital analytics
  • Developing risk-sharing reimbursement models and value based pricing
  • Patient engagement and adherence within the environment
  • Explaining how to use the data sources and observational research for effective safety analysis
  • Dwell ahead of regulatory developments & improving your strategies in a cost effective way Accelerating new medicine introduction in developing world & overcoming challenges
  • Be part of a major networking opportunity


Senior Vice Presidents, Vice Presidents, Senior Executives, Global Heads, Heads, Directors, Senior Managers, Managers of:

Pricing, Reimbursement, Market Access, Commercial Pricing, Pricing Strategists, Health Economics, Outcomes Research, Regulatory Affairs, Governmental Affairs, Public Affairs, Public Policy Directors, Operations, Governmental bodies, Regulatory bodies

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the virtual exhibition area. Expand your knowledge of the latest business models and strategies in the high-level conference.